Skip to search formSkip to main contentSkip to account menu
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
TLDR
Lapatinib plus capecitabine is superior to cape citabine alone in women with HER2-positive advanced breast cancer that has progressed after treatment with regimens that included an anthracycline, a taxane, and trastuzumab.
View on PubMed
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
TLDR
Among patients receiving initial systemic treatment for HR-positive, HER2-negative advanced breast cancer, the duration of progression-free survival was significantly longer among those receiving ribociclib plus letrozole than among those received placebo plus let rozole, with a higher rate of myelosuppression in the ribocIClib group.
View on PubMed
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.
  • D. MilesA. Chan G. Romieu
  • Medicine, Chemistry
    Journal of clinical oncology : official journal…
  • 10 July 2010
TLDR
Bvacizumab 15 mg/kg every 3 weeks significantly increased PFS when combined with docetaxel as first-line therapy for MBC compared with docentaxel plus placebo and had limited impact on the known toxicity profile of docetAXel.
View on PubMed
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker…
TLDR
The addition of lapatinib to capecitabine provides superior efficacy for women with HER2-positive, advanced breast cancer progressing after treatment with anthracycline-, taxane-, and trastuzumab-based therapy.
View on Springer
Challenges to effective cancer control in China, India, and Russia.
View on PubMed
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.
View on PubMed
Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.
  • A. WolffA. Lazar D. Hayes
  • Medicine, Biology
    Journal of clinical oncology : official journal…
  • 10 January 2013
TLDR
Adding temsirolimus to letrozole did not improve PFS as first-line therapy in patients with AI-naive advanced breast cancer, and exploratory analyses of benefit in younger postmenopausal patients require external confirmation.
View on PubMed
Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel,…
TLDR
The results of this trial help define the role of trastuzumab in the breast cancer HER2-positive adjuvant setting, as well as the risks/benefits of adjUvant trastzumab within the context of overall safety including cardiac toxicity.
View via Publisher
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
View on PubMed
First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.
TLDR
The combination of sunitinib plus docetaxel improved ORR but did not prolong either PFS or OS compared with docetAXel alone when given to an unselected HER2/neu-negative cohort as first-line treatment for ABC.
View on PubMed
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License